NewAmsterdam Pharma Co N.V.

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

NAMS$19.18+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

	For the three months ended June 30,		For the six months ended June 30,
	2025	2024	2025	2024
(In thousands of USD, except per share amounts)
Revenue	19,145	2,279	22,123	3,680
Operating expenses:
Research and development expenses	27,516	38,379	72,267	80,809
Selling, general and administrative expenses	27,264	16,475	54,416	30,928
Total operating expenses	54,780	54,854	126,683	111,737
Operating loss	(35,635)	(52,575)	(104,560)	(108,057)
Other income (expense):
Interest income	7,055	4,870	14,406	7,953
Fair value change – earnout	—	3,096	3,992	(5,606)
Fair value change – warrants	2,590	6,596	16,352	(23,652)
Foreign exchange gains/(losses)	8,626	(994)	12,919	(3,412)
Loss before tax	(17,364)	(39,007)	(56,891)	(132,774)
Income tax expense	—	—	—	—
Loss for the period	(17,364)	(39,007)	(56,891)	(132,774)
Other comprehensive income/(loss)
Unrealized gain/(loss) on available-for-sale securities, net of tax	(107)	—	(140)	—
Total comprehensive loss for the period, net of tax	(17,471)	(39,007)	(57,031)	(132,774)
Net loss per ordinary share
Basic and diluted	$(0.15)	$(0.41)	$(0.48)	$(1.45)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.